

Mouse Anti-p16/INK4a [G175-405]: MC0280, MC0280RTU7

Intended Use: For Research Use Only

Description: p16/INK4A is a tumor-suppressor protein and that genetic and epigenetic abnormalities in genes controlling the G1 checkpoint can lead to both escape from senescence and cancer formation. The interaction of p16/INK4 family members can be a binary complex with CDK4/6 or ternary complex with cyclin D-bound CDK4/6 and ultimately results in the inhibition of cell cycle progression. As such, expression of p16 INK4A is commonly associated with cellular senescence, and disruption of the p16 INK4A gene is frequently observed in human tumor. The p16/INK4A locus is deleted in a wide spectrum of tumors including melanoma, pancreatic adenocarcinoma, glioblastoma, certain leukemias, non-small cell lung cancer, cervical cancer, and bladder carcinoma.

Specifications


Clone: G175-405
 Source: Mouse
 Isotype: IgG
 Reactivity: Human
 Localization: Nucleus and/or cytoplasm
 Formulation: Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN₃)
 Storage: Store at 2°- 8°C
 Applications: IHC
 Package:

Description	Catalog No.	Size
p16/INK4a Concentrated	MC0280	1 ml
p16/INK4a Prediluted	MC0280RTU7	7 ml

IHC Procedure*

Positive Control Tissue: Squamous Cell Carcinoma
 Concentrated Dilution: 25-100
 Pretreatment: Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
 Incubation Time and Temp: 30-60 minutes @ RT
 Detection: Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human SCC tissue stained with anti-p16 using DAB

References:

1. Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures. Tong J, et al. Lung Cancer. Nov;74(2):155-63, 2011.
2. Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters. Ohtsubo K, et al. J Gastroenterol. 38(7):663-71, 2003.
3. Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. Geradts J, et al. Appl Immunohistochem Mol Morphol. Mar;8(1):71-9, 2000.
4. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Hu YX, et al. Clin Cancer Res. 1997 Sep;3(9):1473-7, 1997.